Vanda Pharmaceuticals (VNDA) Stock Price, Quote & News

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for prev...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States

Valueforall Aug. 16 at 1:50 PM

$VNDA Beyond the analyst lowballs, Vanda is sitting on an ironclad valuation floor with $200M+ in cash, a ~300-rep sales force driving Fanapt's bipolar ramp, and a massive M&A bid floor ($8/share) that the market completely ignores

1 · Reply

mciuzelis Aug. 15 at 12:56 PM

Some interesting development is going on eith portfolio stocks. PART 2 $VNDA knocked down biotech, w MC slighly above sales, 3 FDA-approved drugs and a strong pipeline. Several BO order already rejected as too low with 80% premium the current market price. My largest position. $SRPT extrmely depressed biotech w $1.5B in sales, $700M cash, strong pipeline. New CEO just started, a lot might be expected, M&A incl. Very good stock for trading, as it stuck in a $15-25 range for more than a year already. $VRRM after lossing a key 12-13% revenue customer stock crashed by 70% erasing $3B of MC. The same customer returned, MC - still not. Potential Mulibagger perfirmaner.

0 · Reply

Trendrebel Aug. 15 at 9:11 AM

$VNDA For some reason VNDA has always been technical reliable. Chart is not pretty, but still promising short term. Trend is DOWN. But as mentioned earlier, it will go to 5.70 according to the daily chart and ext. Fibonacci here. It also match perfect to MA50. If you look at the weekly trendline ( purple )... It will be resistance, if we get any positive fundamental news.

1 · Reply

TomMac64 Aug. 14 at 8:06 PM

$VNDA Good day bulls !

1 · Reply

Valueforall Aug. 14 at 7:47 PM

$VNDA adding as it goes higher

0 · Reply

prismmarketview Aug. 14 at 1:37 PM

$150 million is going behind the next stage of schizophrenia drug development. MapLight Therapeutics ($MPLT) raised $150M following positive Phase 2 results for ML-007C-MA, including a signal in cognition. Across the field, companies are targeting different gaps in schizophrenia care: longer-acting treatments at $TEVA, a newly approved option from $VNDA, and negative symptoms at $NERV. The pipeline is moving beyond controlling psychosis toward addressing more of the disease’s full burden. https:// prismmarketview.com/maplight-raise s-150-million-as-schizophrenia-drug-development-broadens/ $MPLT $TEVA $VNDA $NERV

1 · Reply

Cheesyisi Aug. 13 at 2:34 AM

$VNDA

0 · Reply

TomMac64 Aug. 13 at 12:51 AM

$VNDA

3 · Reply

dl42 Aug. 13 at 12:28 AM

$VNDA is SuperDuper out of VNDA? She has not posted in a week.

0 · Reply

TomMac64 Aug. 12 at 3:21 PM

$VNDA Agree !

0 · Reply

Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley

2026-08-10T10:10:14.000Z - 6 days ago

Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright

Aug 5, 2026, 4:30 PM EDT - 10 days ago

Vanda Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 10 days ago

Vanda Pharmaceuticals Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 10 days ago

Vanda Pharmaceuticals Quarterly report: Q2 2026

2026-08-05T20:06:21.000Z - 10 days ago

Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year

2026-08-05T20:05:57.000Z - 10 days ago

Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M

Aug 5, 2026, 4:01 PM EDT - 10 days ago

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Jul 29, 2026, 4:31 PM EDT - 17 days ago

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

2026-07-16T20:35:23.000Z - 4 weeks ago

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

Jul 16, 2026, 4:30 PM EDT - 4 weeks ago

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Jul 15, 2026, 4:30 PM EDT - 4 weeks ago

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Jul 10, 2026, 4:30 PM EDT - 5 weeks ago

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

2026-07-07T20:50:18.000Z - 5 weeks ago

Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A

Jul 7, 2026, 4:30 PM EDT - 5 weeks ago

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Jun 4, 2026, 9:00 AM EDT - 2 months ago

Vanda Pharmaceuticals Transcript: AGM 2026

2026-05-27T11:24:38.000Z - 2 months ago

Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan

May 27, 2026, 7:00 AM EDT - 2 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

May 19, 2026, 2:00 PM EDT - 3 months ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 18, 2026, 7:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

2026-05-11T10:50:03.000Z - 3 months ago

Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright

May 7, 2026, 6:44 PM EDT - 3 months ago

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

2026-05-07T01:52:21.000Z - 3 months ago

Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year

2026-05-07T01:50:55.000Z - 3 months ago

Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M

May 6, 2026, 4:30 PM EDT - 3 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Vanda Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Vanda Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:01 PM EDT - 3 months ago

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

2026-05-04T12:46:08.000Z - 3 months ago

Vanda Pharmaceuticals announces U.S. commercial availability of Nereus

May 4, 2026, 8:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

2026-05-01T20:40:19.000Z - 3 months ago

Vanda Pharmaceuticals announces commercial availability for Nereus

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 28, 2026, 7:12 PM EDT - 3 months ago

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

ANAB

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 5:13 PM EDT - 4 months ago

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

2026-04-09T15:10:15.000Z - 4 months ago

Vanda calls on FDA to remove proposal extending drug review timelines

Apr 9, 2026, 11:02 AM EDT - 4 months ago

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

2026-04-08T20:50:15.000Z - 4 months ago

Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting

Apr 8, 2026, 4:44 PM EDT - 4 months ago

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Mar 19, 2026, 4:34 PM EDT - 5 months ago

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Mar 11, 2026, 2:15 PM EDT - 5 months ago

Vanda Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 6, 2026, 6:00 AM EST - 5 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

2026-03-05T11:11:50.000Z - 5 months ago

Vanda Pharmaceuticals initiated with a Buy at Truist

2026-03-03T13:05:54.000Z - 5 months ago

Vanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz

Mar 3, 2026, 8:01 AM EST - 5 months ago

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

Feb 26, 2026, 4:35 PM EST - 6 months ago

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

Feb 25, 2026, 7:18 AM EST - 6 months ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Feb 23, 2026, 10:28 AM EST - 6 months ago

Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

Feb 20, 2026, 6:03 PM EST - 6 months ago

US FDA approves Vanda's psychiatric drug

Feb 20, 2026, 5:59 PM EST - 6 months ago

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Feb 12, 2026, 7:00 AM EST - 6 months ago

Vanda Pharmaceuticals Registration statement: Registration Filing

Feb 11, 2026, 4:30 PM EST - 6 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Vanda Pharmaceuticals Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Vanda Pharmaceuticals Earnings release: Q4 2025

Feb 11, 2026, 4:01 PM EST - 6 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 4, 2026, 6:01 PM EST - 6 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 15, 2026, 12:00 PM EST - 7 months ago

Vanda Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 7:00 AM EST - 7 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

Jan 8, 2026, 9:31 AM EST - 7 months ago

Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 7:00 AM EST - 7 months ago

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Dec 31, 2025, 10:57 AM EST - 8 months ago

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Dec 30, 2025, 6:30 PM EST - 8 months ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:13 PM EST - 8 months ago

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

Dec 15, 2025, 7:00 AM EST - 8 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Dec 11, 2025, 5:02 PM EST - 8 months ago

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:21 PM EST - 9 months ago

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 28, 2025, 7:00 AM EST - 9 months ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 17, 2025, 6:37 PM EST - 9 months ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 12, 2025, 4:40 PM EST - 9 months ago

Vanda Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 9, 2025, 6:00 PM EST - 9 months ago

Vanda Pharmaceuticals Slides: Corporate Presentation

Nov 5, 2025, 5:00 PM EST - 10 months ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Earnings release: Q3 2025

Oct 29, 2025, 4:01 PM EDT - 10 months ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 11 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 11 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 1 year ago

Vanda Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 5:23 PM EDT - 1 year ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 1 year ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 1 year ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Quarterly report: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Earnings release: Q2 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 4:45 PM EDT - 1 year ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Valueforall Aug. 16 at 1:50 PM

1 · Reply

mciuzelis Aug. 15 at 12:56 PM

0 · Reply

Trendrebel Aug. 15 at 9:11 AM

1 · Reply

TomMac64 Aug. 14 at 8:06 PM

$VNDA Good day bulls !

1 · Reply

Valueforall Aug. 14 at 7:47 PM

$VNDA adding as it goes higher

0 · Reply

prismmarketview Aug. 14 at 1:37 PM

1 · Reply

Cheesyisi Aug. 13 at 2:34 AM

$VNDA

0 · Reply

TomMac64 Aug. 13 at 12:51 AM

$VNDA

3 · Reply

dl42 Aug. 13 at 12:28 AM

$VNDA is SuperDuper out of VNDA? She has not posted in a week.

0 · Reply

TomMac64 Aug. 12 at 3:21 PM

$VNDA Agree !

0 · Reply

TomMac64 Aug. 12 at 3:21 PM

$VNDA

0 · Reply

BullMaven Aug. 12 at 3:14 PM

$VNDA one of best small cap bio

0 · Reply

TomMac64 Aug. 12 at 3:06 PM

$VNDA

0 · Reply

Its_Only_Money_369 Aug. 12 at 2:57 PM

$VNDA There’s been some strong accumulation here since we dropped below 5. Expecting upward momentum until 5.80, then a smack down to 4.20-3.80.

1 · Reply

VictorJung Aug. 12 at 2:44 PM

$VNDA were ripping!!! ↗️↗️↗️

0 · Reply

BullMaven Aug. 11 at 7:34 PM

$VNDA added 1k 4.86

0 · Reply

HFlier Aug. 11 at 7:34 PM

$VNDA One last liquidity grab. Buy on the drop.

0 · Reply

VSTN Aug. 11 at 6:39 PM

$VNDA This one needs a life line.

0 · Reply

johnle66 Aug. 11 at 3:45 PM

$VNDA Best small bio on the market, just a matter of time and I have plenty.

0 · Reply

TomMac64 Aug. 11 at 4:37 AM

$VNDA When you rest your head tonight be thankful we’ve been public for 20 years and we have a massive float of 60M (tongue in cheek) and that in all likelihood isn’t gonna change for at least the next 3 qrts man I sleep good at night !

0 · Reply

pablo4 Aug. 10 at 8:30 PM

$VNDA I actually think analysts are setting VNDA up nicely.....analysts are in a "prove it" mode....understandable. But that mindset means expectations are low, making it easier for VNDA to outperform. VNDA has predicted revenues of 138 to 188M for the last 6 months of this year with the midpoint of 163M. The lowest analyst estimate for the six months is 135.8M (below VNDA mgt's low end). The highest analyst estimate is 159M (below VNDA's midpoint of 163M...way below high estimate of 188M). I'll link the analyst info below. Just scroll down to see Revenue Estimate and then add the low estimates for the next 2 quarters and the high estimates for the next 2 quarters to see where my numbers come from. Overall, mgt. set an annual rev projection of 240 to 290M....midpoint 265M. You'll see the analysts' range is 243 (should show 238) to 262...midpoint of 254 (weighted). Yes, the next 2 quarters is VNDA's chance to outperform and drive stock price up, IMO. https://finance.yahoo.com/quote/VNDA/analysis/

1 · Reply

pablo4 Aug. 10 at 6:58 PM

$VNDA there is still the gap from Nov. 14, 2025 you can find easily by looking at the historical price vs. trying to see on a chart. It is exactly at 4.40. We traded after earnings at 4.45 but did not close the gap. Given the outlook, I can't see us closing the gap at 4.40 but VNDA is a crazy stock too. I'll sure be re-grabbing those trading shares back (I wrote of after earnings here just the other day) if it tries to close that gap again. I don't care what the Riley analyst says today as to moving the target from 17 to 12.....VNDA's future is getting near....that is, the future that is going to move the market cap toward new highs.....JMO. It's not the time to be lowering targets, IMO.

0 · Reply

Market Cap	315.62M
Revenue (ttm)	216.11M
Net Income (ttm)	-220.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.02%
Debt to Equity Ratio	0.00

Volume	965,000
Avg Vol	954,000
Day's Range	N/A - N/A
Shares Out	60.46M
Stochastic %K	80%
Beta	0.64
Analysts	Strong Sell
Price Target	$12.19